Keywords: Vivus, Qsymia, Weight loss, Obesity, US sales, Express Scripts

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts

Article | 10 October 2012

Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release) rose 432% sequentially in its second week ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Vivus

Express Scripts

Go to company listing

Related Drugs

Qsymia

Go to drug listing